



Published in final edited form as:

Nat Commun. ; 5: 5872. doi:10.1038/ncomms6872.

## Histone acetylation mediated by Brd1 is crucial for *Cd8* gene activation during early thymocyte development

Yuta Mishima<sup>1,2,3,4,\*</sup>, Changshan Wang<sup>1,3,\*</sup>, Satoru Miyagi<sup>1,3,\*</sup>, Atsunori Saraya<sup>1,3,\*</sup>, Hiroyuki Hosokawa<sup>5</sup>, Makiko Mochizuki-Kashio<sup>1,3</sup>, Yaeko Nakajima-Takagi<sup>1,3</sup>, Shuhei Koide<sup>1,3</sup>, Masamitsu Negishi<sup>1</sup>, Goro Sashida<sup>1,3</sup>, Taku Naito<sup>6</sup>, Tomoyuki Ishikura<sup>7</sup>, Atsushi Onodera<sup>5</sup>, Toshinori Nakayama<sup>5</sup>, Daniel G. Tenen<sup>4</sup>, Naoto Yamaguchi<sup>2</sup>, Haruhiko Koseki<sup>7</sup>, Ichiro Taniuchi<sup>8</sup>, and Atsushi Iwama<sup>1,3</sup>

<sup>1</sup>Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

<sup>2</sup>Department of Molecular Cell Biology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

<sup>3</sup>JST, CREST, 7 Gobancho, Chiyoda-ku, Tokyo 102-0076, Japan

<sup>4</sup>Cancer Science Institute, National University of Singapore, and Harvard Stem Cell Institute, Harvard Medical School, 3 Blackfan Circle, Boston, Massachusetts 02115, USA

<sup>5</sup>Department of Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

<sup>6</sup>Department of Molecular Immunology, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan

<sup>7</sup>Laboratory for Developmental Genetics, RIKEN Research Center for Integrative Medical Sciences, IMS-RCI, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan

<sup>8</sup>Laboratory for Transcriptional Regulation, RIKEN Research Center for Integrative Medical Sciences, IMS-RCI, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan

### Abstract

During T-cell development, *Cd8* expression is controlled via dynamic regulation of its *cis*-regulatory enhancer elements. Insufficiency of enhancer activity causes variegated *Cd8* expression in CD4<sup>+</sup>CD8<sup>+</sup> double-positive (DP) thymocytes. Brd1 is a subunit of the Hbo1 histone

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

Correspondence and requests for materials should be addressed to A.I. (aiwama@faculty.chiba-u.jp).

\*These authors contributed equally to this work.

#### Author contributions

Y.M., C.W., S.M., A.S. and I.T. designed and performed experiments, analysed data and wrote the manuscript; H.H., M.M.-K., Y.N.-T., G.S. and S.K. designed and performed experiments and provided intellectual input; M.N., A.O., T. Nakayama, D.G.T. and N.Y. provided intellectual input on experimental design and interpretation of results; T. Naito, T.I. and H.K. provided key reagents and assistance with experimental design and interpretation; A.I. led the investigation, devised the project and wrote the manuscript. All authors reviewed and edited the manuscript.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

acetyltransferase (HAT) complex responsible for acetylation of histone H3 at lysine 14 (H3K14). Here we show that deletion of *Brd1* in haematopoietic progenitors causes variegated expression of *Cd8*, resulting in the appearance of CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes indistinguishable from DP thymocytes in their properties. Biochemical analysis confirms that Brd1 forms a HAT complex with Hbo1 in thymocytes. ChIP analysis demonstrates that Brd1 localizes at the known enhancers in the *Cd8* genes and is responsible for acetylation at H3K14. These findings indicate that the Brd1-mediated HAT activity is crucial for efficient activation of *Cd8* expression via acetylation at H3K14, which serves as an epigenetic mark that promotes the recruitment of transcription machinery to the *Cd8* enhancers.

---

During T-cell development, expression of the *Cd4* and *Cd8* co-receptor genes, which are required for differentiation of helper- and killer-lineage T cells, respectively, is strictly regulated. Extensive studies have proposed that stage- and lineage-specific expression of *Cd8a* and *Cd8b1* genes is regulated by combined regulation of at least five different *Cd8* enhancers (E8<sub>I</sub>–E8<sub>V</sub>) in the *Cd8* locus<sup>1</sup>. Manipulation of *Cd8* enhancers in mice has unravelled the role of each enhancer in *Cd8* gene regulation. Importantly, variegated expression of CD8 in double-positive (DP) thymocytes is observed in mice with combined deletion of E8<sub>I</sub> and E8<sub>II</sub> or deletion of E8<sub>II</sub> and E8<sub>III</sub> enhancers<sup>2–4</sup>. Similarly, among transcription factors implicated in the regulation of *Cd8* enhancers, combined deletion of genes of *Ikaros* family (*Ikaros*<sup>+/-</sup>*Aiolos*<sup>-/-</sup>) was shown to cause variegated CD8 expression in DP thymocytes<sup>5</sup>. This *Cd8* variegation also occurs in mice with attenuated activity of the BAF (Brahma-related gene/Brahma-associated factor) chromatin-remodelling complex. Haplo-insufficiency of Brg1, which is an ATPase required for BAF-mediated chromatin remodelling, leads to the appearance of CD8-negative DP cells, suggesting a link between *Cd8* enhancers and the BAF chromatin remodelling complex<sup>6</sup>. Moreover, variegated CD8 expression could be partially reverted by intercrossing E8<sub>I</sub>/E8<sub>II</sub> doubly deficient mice with *DNA methyltransferase 1* (*Dnmt1*)-deficient mice<sup>7</sup>. These findings suggest a link between transcription factors such as *Ikaros* and inhibition of DNA methylation in *Cd8* gene activation. However, it remains unclear whether histone modifications are crucial for *Cd8* gene activation.

The histone acetyltransferases (HATs) of the MYST family include Tip60, Hbo1, Moz/Morf and Mof and function in multisubunit protein complexes. We previously reported that Bromodomain-containing protein 1 (Brd1), also known as Brpf2, forms a novel HAT complex with Hbo1 and is responsible for the global acetylation of histone H3 at lysine 14 (H3K14)<sup>8</sup>. However, because of embryonic lethality of *Brd1*<sup>-/-</sup> mice, the function of Brd1 in regulating lymphopoiesis remains uncharacterized. In this study, we generated mice in which Brd1 is inactivated in haematopoietic progenitors and found that Brd1 plays a crucial role in the induction of CD8 expression at several stages of T-lymphocyte development. Our findings revealed that H3K14 acetylation by Brd1 is essential for efficient activation of the *Cd8* gene.

## Results

### Deregulated T-cell development in *Brd1*-deficient thymus

We previously reported that *Brd1*<sup>-/-</sup> mice die from severe anaemia by E13.5 or earlier<sup>8</sup>. To understand the role of Brd1 in adult haematopoiesis, we generated mice harbouring *Brd1*<sup>fl/fl</sup> mutation in which exon 2 containing the first ATG is floxed (Fig. 1a) and then crossed *Brd1*<sup>fl/fl</sup> mice with *Tie2-Cre* mice that specifically express Cre in haematopoietic and endothelial cells (*Tie2-Cre;Brd1*<sup>fl/fl</sup> mice)<sup>9</sup>. Complete deletion of *Brd1* in peripheral blood (PB) CD45<sup>+</sup> mononuclear haematopoietic cells was confirmed by genomic PCR (Supplementary Fig. 1). In contrast to germline deletion, which causes lethal anaemia in embryos, deletion of *Brd1* in haematopoietic and endothelial cells resulted in a mild differentiation block in erythroblasts in the fetal liver, thus allowing *Tie2-Cre;Brd1*<sup>fl/fl</sup> mice to be born and grow normally.

Detailed analysis of the lymphoid organs, however, revealed abnormal thymocyte differentiation. Although thymic cellularity of the *Tie2-Cre;Brd1*<sup>fl/fl</sup> mice was comparable to that of the control mice (Fig. 1b), the pattern of CD4/CD8 expression was significantly altered (Fig. 1c). The proportion of CD4 single-positive (SP) thymocytes was significantly increased while that of DP and CD8 SP thymocytes was decreased (Fig. 1c). Analyses of T-cell antigen receptor (TCR)  $\beta$  expression revealed that a proportion of CD4 SP thymocytes of *Tie2-Cre;Brd1*<sup>fl/fl</sup> mice expressed no or low levels of TCR $\beta$  (TCR $\beta$ <sup>-/low</sup>) like control DP thymocytes (Fig. 1d). DP thymocytes in *Tie2-Cre;Brd1*<sup>fl/fl</sup> mice were reduced twofold compared with the control mice. Instead, the CD4<sup>+</sup>TCR $\beta$ <sup>-/low</sup> thymocytes were found at a frequency comparable to that of DP thymocytes in *Tie2-Cre;Brd1*<sup>fl/fl</sup> mice (Fig. 1e). In contrast, the frequency of bona fide CD4<sup>+</sup>TCR $\beta$ <sup>high</sup> SP thymocytes in *Tie2-Cre;Brd1*<sup>fl/fl</sup> mice was comparable to that of the control mice (Fig. 1e). Interestingly, the level of CD8 expression in *Brd1*<sup>-/-</sup> thymocytes was moderately but significantly lower than that of the control, with the mean fluorescent intensity (MFI) of DP and CD8 SP thymocytes in flow cytometric analysis being 66.1% and 80.8% of the control, respectively (Fig. 1f). To better distinguish mature from immature thymocytes and reveal their CD4 and CD8 coreceptor expression patterns in *Tie2-Cre;Brd1*<sup>fl/fl</sup> mice, we fractionated thymocytes for their expression of TCR $\beta$  and CD69 (Supplementary Fig. 2). As expected, WT TCR $\beta$ <sup>-</sup>CD69<sup>-</sup> thymocytes were mostly CD4<sup>+</sup>CD8<sup>+</sup> DP thymocytes, whereas *Brd1*<sup>-/-</sup> thymocytes contained a large number of CD4 SP cells along with DP cells, suggesting that the large portion of CD4 SP cells are at a similar differentiation stage to DP thymocytes. Of interest, a significant portion of *Brd1*<sup>-/-</sup> mature TCR $\beta$ <sup>+</sup>CD69<sup>+</sup> and TCR $\beta$ <sup>+</sup>CD69<sup>-</sup> thymocytes appeared as CD4<sup>-/low</sup>CD8<sup>-</sup> subset. This result may reflect that some MHC class I-selected thymocytes during maturation towards the CD8 lineage are unable to express CD8 (Supplementary Fig. 2). In addition, CD4<sup>-/low</sup>CD8<sup>-</sup> cells were detected also in the immature TCR $\beta$ <sup>-</sup>CD69<sup>-</sup> fraction, suggesting that failure of *Cd8* gene activation at the transition from DN to DP stage in the absence of Brd1 allows a significant portion of *Brd1*<sup>-/-</sup> DN cells to differentiate into CD4<sup>+</sup>TCR $\beta$ <sup>-/low</sup> thymocytes directly via CD4<sup>low</sup>TCR $\beta$ <sup>-/low</sup> intermediate stage (Supplementary Fig. 2).

We next analysed mature T-cell pools in the periphery, and found that the frequency of mature CD8<sup>+</sup> T cells in PB was decreased to 50% of the control (Fig. 1g and Supplementary Fig. 3). All CD4<sup>+</sup> T cells showed a high level of TCR $\beta$  expression and no CD4<sup>+</sup>CD8<sup>-</sup>TCR<sup>-low</sup> T cells were detected in the PB of *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice (Supplementary Fig. 3). Among TCR $\beta$ <sup>+</sup> cells, however, there was a mild increase in the population of CD4<sup>-</sup>CD8<sup>-</sup> cells in the PB of *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice compared with the controls. It is possible that some class I-restricted cells in the PB are phenotypically CD8<sup>-</sup>CD4<sup>-</sup> due to the compromised expression of CD8 (Supplementary Fig. 3).

### Cell autonomous defect of T cells in the absence of Brd1

The *Tie2* promoter drives Cre expression not only in haematopoietic cells, but also in endothelial cells<sup>9</sup>. To exclude any influence of loss of *Brd1* on the thymic microenvironment, we transplanted BM cells from *Tie2-Cre* control and *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice (CD45.2<sup>+</sup>) with the same number of BM competitor cells (CD45.1<sup>+</sup>) into lethally irradiated wild-type recipient mice (CD45.1<sup>+</sup>). Recipient mice reconstituted with *Brd1<sup>-/-</sup>* BM cells showed abnormal thymocyte differentiation similar to that in the *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice (Fig. 2a,b). *Brd1<sup>-/-</sup>* T cells were markedly outcompeted by the T cells derived from the competitor cells in the PB (Fig. 2c). We therefore transplanted BM cells from *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice without competitor cells and again found that *Brd1<sup>-/-</sup>* T cells, particularly CD8<sup>+</sup> T cells, were outcompeted by the residual host T cells (Fig. 2d). These results indicate that the appearance of abnormal CD4<sup>+</sup>CD8<sup>-</sup>TCR $\beta$ <sup>-low</sup> thymocytes and the inefficient production of mature CD8<sup>+</sup> T cells are intrinsic to *Brd1<sup>-/-</sup>* cells.

Given the essential requirement for CD8 as a co-receptor to support the differentiation of CD8 T cells, it is likely that the low CD8 expression in the thymus is causal for the reduction of CD8 T cells. However, *Brd1<sup>-/-</sup>* CD4 T cells also showed significantly lower chimerism in PB in competitive repopulation experiments (Fig. 2d). We therefore tested the ability of *Brd1<sup>-/-</sup>* peripheral CD4 T cells to repopulate in immuno-compromised host mice. We transferred  $1 \times 10^6$  CD45.2 CD4 T cells from the *Tie2-Cre* control and the *Tie2-Cre;Brd1<sup>fl/fl</sup>* spleen into sublethally irradiated NOG mice along with the same number of CD45.1 splenic CD4 T cells (competitor cells). *Brd1<sup>-/-</sup>* CD4 T cells established chimerism that is comparable to or rather higher than that of the control cells (Fig. 2e). Considering that the number of *Brd1<sup>-/-</sup>* CD4<sup>+</sup>TCR $\beta$ <sup>high</sup> SP thymocytes is comparable to that of the WT control, these results suggest that the reduced chimerism of *Brd1<sup>-/-</sup>* CD4 T cells in the periphery could be attributed to the impaired egress from the thymus to the periphery. To test this hypothesis, we checked the expression of S1P receptors (S1P<sub>1-5</sub>), which regulate the egress of T cells from the thymus<sup>10</sup>. Although expression of S1P<sub>1</sub>, which is critical for CD4 SP thymocytes to egress from the thymus<sup>10</sup>, showed a trend of reduction in *Brd1<sup>-/-</sup>* CD4<sup>+</sup>TCR $\beta$ <sup>high</sup> thymocytes, it did not give a statistical significance (Fig. 2f).

These findings suggest that Brd1 is necessary to endow appropriate integrity to CD4 T cells in the periphery. We then examined whether Brd1 was required for CD4 T-cell function. We purified splenic naive CD4 T cells from WT and *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice and cultured them under Th1 or Th2 conditions *in vitro*. Intriguingly, the numbers of both IFN $\gamma$ -producing cells under Th1 conditions and IL-4-producing cells under Th2 conditions were decreased

substantially by loss of Brd1 (Supplementary Fig. 4). These findings indicate that Brd1 is also required for efficient cytokine production by peripheral CD4 T cells.

### Variegated Cd8 expression in the absence of Brd1

We next characterized the cell cycle status of *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes reconstituted in wild-type thymic environment using a BrdU incorporation assay. Both control and *Brd1*<sup>-/-</sup> DP thymocytes contained a significant proportion of cycling cells, whereas CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>high</sup> and CD8 SP thymocytes did not (Fig. 3a). Of note, *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes contained cycling cells at the same frequency as DP thymocytes.

Furthermore, hierarchical clustering of gene expression profile in several thymocyte fractions from *Brd1*<sup>+/+</sup> and *Brd1*<sup>-/-</sup> mice revealed that *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes have an expression profile highly similar to DP thymocytes, particularly to *Brd1*<sup>-/-</sup> DP thymocytes, but quite different from mature (TCRβ<sup>hi</sup>) CD4 SP thymocytes of both *Brd1*<sup>+/+</sup> and *Brd1*<sup>-/-</sup> genotypes (Fig. 3b,c). Quantitative RT-PCR confirmed that *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes express genes specific to DP thymocytes, such as *Myb* and *Rag1* (refs 11,12), but not *Cd8a* and *Cd8b1* (Fig. 3d and Supplementary Table 1). Expression of key regulator genes of *Cd8* transcription, such as *Ikaros*, *Runx1* and *Runx3*, was not altered in *Brd1*<sup>-/-</sup> DP and CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes compared with that in WT DP thymocytes (Supplementary Table 1). These results indicate that *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes correspond to immature thymocytes that would normally appear as DP thymocytes. Correspondingly, expression of *Zbtb7b* that encodes ThPOK, a master regulator of CD4 helper T cells, was not detected in *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes as was not detected in WT DP thymocytes. However, its expression in *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>high</sup> thymocytes was comparable to that in WT CD4 SP thymocytes (Fig. 3d).

To investigate whether the lack of Brd1 affects the direction of class I-restricted thymocytes to CD8 SP cells, we crossed *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice with mice expressing OT-I MHC class I-restricted transgenic TCR<sup>13</sup>. As expected, the vast majority of *Brd1*<sup>-/-</sup> DP thymocytes appeared as CD8<sup>-</sup> DP (CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup>) thymocytes (Fig. 3e). However, some of the canonical *Brd1*<sup>-/-</sup> DP thymocytes were positively selected and differentiated into mature CD8 SP thymocytes. In the PB, CD8<sup>+</sup> T cells dominated even in the absence of Brd1, although they exhibited a reduced level of CD8 expression (Fig. 3f). On the basis of these findings, we conclude that *Brd1* deficiency causes variegated expression of CD8 due to inefficient activation of the *Cd8* gene.

Of interest, expression of *Brd1* is upregulated during transition of DN to DP stage and is downregulated afterwards (Fig. 3d). Thus, it is possible that an increase in the amount of Brd1 is necessary to initiate *Cd8* activation during the DN to DP transition. To test this notion, we cultured DN3 cells on TSt-4/DLL stromal cells and monitored their differentiation. As clearly demonstrated in Fig. 4, the majority of *Brd1*<sup>-/-</sup> DN3 cells differentiated into CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> thymocytes without going through the CD4<sup>+</sup>CD8<sup>+</sup> DP stage. These findings well correspond to the *in vivo* finding that a small but

significant subpopulation of TCR $\beta$ <sup>-</sup>CD69<sup>-</sup> immature thymocytes exhibits a CD4<sup>-/low</sup> CD8<sup>-</sup> phenotype in the *Tie2-Cre;Brd1<sup>fl/fl</sup>* thymus (Fig. 1c and Supplementary Fig. 2).

We next examined the apoptotic status of *Brd1*<sup>-/-</sup> CD8 SP thymocytes with lower CD8 expression and found that they do not show any enhancement in apoptotic cell death compared with the control cells (Annexin V<sup>+</sup> cells; *Brd1*<sup>+/+</sup> 8.4%, *n* = 2 versus *Brd1*<sup>-/-</sup> 6.1%, *n* = 2).

### Impaired reactivation of *Cd8* in *Brd1*<sup>-/-</sup> peripheral T cells

In the gut intraepithelial lymphocyte (IEL) compartment, there are three cell subsets expressing the *Cd8a* gene other than conventional CD8 $\alpha\beta$ <sup>+</sup> cytotoxic T cells;  $\gamma\delta$ T cells, CD8 $\alpha\alpha$ <sup>+</sup> and CD4<sup>+</sup>CD8 $\alpha\alpha$ <sup>+</sup>  $\alpha\beta$ T cells<sup>14</sup>. We therefore examined CD8 expression in those cells. Of interest, the population of CD8 $\alpha\alpha$ <sup>+</sup> and CD4<sup>+</sup>CD8 $\alpha\alpha$ <sup>+</sup>  $\alpha\beta$ T cells were significantly decreased in *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice compared with the *Tie2-Cre* control mice (Fig. 5). In addition, the percentage of CD8 $\alpha\alpha$  expressing  $\gamma\delta$ T cells was significantly reduced (Fig. 5). We interpreted the reduction in CD8 $\alpha\alpha$ <sup>+</sup>  $\gamma\delta$ T cells as a reflection of variegated CD8 expression in  $\gamma\delta$ T cells in the gut. It has also been reported that CD4<sup>+</sup>CD8 $\alpha\alpha$ <sup>+</sup> IELs are differentiated from CD4<sup>+</sup> T cells by reactivating the *Cd8a* gene after the downregulation of Th-POK, a master regulator of CD4 helper T cells<sup>15</sup>. Together, these findings suggest that *Brd1* is required to initiate *Cd8a* activation in  $\gamma\delta$ T cells as well as *Cd8* reactivation in CD4<sup>+</sup> T cells in the gut.

### *Brd1*-Hbo1 complex is responsible for H3K14 acetylation at *Cd8* gene loci

To confirm that *Brd1* acts as a histone modifier, we compared levels of histone acetylation between *Tie2-Cre* and *Tie2-Cre;Brd1<sup>fl/fl</sup>* thymi. As we reported previously in *Brd1*<sup>-/-</sup> erythroblasts<sup>8</sup>, the global level of H3K14 acetylation was profoundly decreased in *Brd1*<sup>-/-</sup> thymocytes, whereas the levels of H3K9, H4K5, K8, K12 and K16 were not significantly changed (Fig. 6a). Biochemical analysis also confirmed that *Brd1* forms a HAT complex with Hbo1 and Ing4/5 in the AKR1 DP T cell line expressing 3xFlag-*Brd1* (AKR1/*Brd1* cells) (Supplementary Fig. 5). Chromatin immunoprecipitation (ChIP) assays of AKR1/*Brd1* and AKR1/Hbo1 cells confirmed that *Brd1* and Hbo1 bind to the enhancers and promoters of the *Cd8* genes, respectively (Fig. 6b). ChIP assays also revealed drastic reduction in levels of H3K14 acetylation at the enhancers and promoters of the *Cd8a* and *Cd8b1* loci in *Brd1*<sup>-/-</sup> DP thymocytes and even more reduction in *Brd1*<sup>-/-</sup> CD8<sup>-</sup> DP thymocytes. In contrast, the reduction was only moderate at the *Cd4* silencer in both *Brd1*<sup>-/-</sup> DP and CD8<sup>-</sup> DP thymocytes, which express CD4 (Fig. 6b). These findings suggest that the Hbo1-*Brd1* HAT complex acetylates H3K14 at the transcriptional regulatory elements of the *Cd8* gene, and that this step is necessary for efficient activation of the *Cd8* gene.

HATs are known to collaborate with the transcription factors critical for the transcriptional activation of the given genes. We therefore searched for physical interactions between the Hbo1-*Brd1* HAT with Runx family transcription factors and Ikaros, which are known critical regulators that activate the *Cd8* genes<sup>5,16</sup>. To identify physical interactions, we co-transfected 293T cells with Runx1 or Runx3 together with either *Brd1* or Hbo1 and performed immunoprecipitation. Both *Brd1* and Hbo1 were readily co-immunoprecipitated



with Runx1 and Runx3 (Fig. 6c). These direct interactions were confirmed by GST-pull down assays using GST-Runx1 and GST-Runx3 and *in vitro* translated Brd1 and Hbo1 (Fig. 6c). We also detected co-immunoprecipitation of Ikaros with Brd1 or Hbo1 in 293T cells in a similar transfection assay (Fig. 6d). These results support the idea of crosstalk between transcription factors and the Hbo1-Brd1 HAT complex in the activation of *Cd8* genes.

Finally, to confirm the role of Brd1 in the initial activation of *Cd8* gene, we transduced *Brd1*<sup>-/-</sup> DN cells with a *Brd1* retrovirus and cultured them on TSt-4/DLL stromal cells. Defective CD8 expression on differentiating *Brd1*<sup>-/-</sup> DN cells was completely rescued by exogenous Brd1, allowing *Brd1*<sup>-/-</sup> DN cells to become DP cells *in vitro* (Fig. 7a). Corresponding to this finding, the global level of acetylation at H3K14 in DP cells was largely restored by retroviral complementation of Brd1 (Fig. 7b). These results confirm the critical role of the acetylation at H3K14 by the Hbo1-Brd1 HAT complex in the transcriptional activation of *Cd8* gene.

## Discussion

In this study, variegated expression of CD8 was observed in *Brd1*<sup>-/-</sup> DP thymocytes in a manner similar to DP thymocytes with insufficient activity of *Cd8* enhancers<sup>2-4</sup>. Several molecules have been implicated in the regulation of *Cd8* enhancers, including *Ikaros* and *Runx* family transcription factors<sup>5,16</sup>, BAF chromatin-remodelling complex<sup>6</sup> and *Dnmt1*<sup>7</sup>. However, the role of histone modifications has never been characterized before.

N-terminal tail domains of histones are acetylated in the promoter region of actively transcribed genes<sup>17</sup>. Acetyl-lysine residues are recognized by bromodomain-containing factors. Although the role of acetylation at H3K14 is not well understood, it has been reported that several bromodomain-containing proteins such as BAF57, a subunit of the BAF chromatin remodelling complex, and TAFII250, which recruits TFIID, bind to acetylated H3K14 (refs 18,19). Indeed, compromised BAF activity causes variegated CD8 expression in a manner similar to that caused by the loss of Brd1, suggesting a functional crosstalk between the Hbo1-Brd1 HAT complex and the BAF complex<sup>6</sup>. It is therefore possible that the Hbo1-Brd1 complex is involved in the chromatin relaxation via H3K14 acetylation, which is followed by subsequent recruitment of transcriptional complexes at the *Cd8* enhancers for full activation of the *Cd8* locus.

Although the expression of CD8 on the cell surface was moderately decreased in *Brd1*<sup>-/-</sup> DP and CD8 SP thymocytes and *Brd1*<sup>-/-</sup> CD8<sup>+</sup> T cells in the PB, mRNA expression of *Cd8a* and *Cd8b1* genes in these CD8 expressing *Brd1*<sup>-/-</sup> cells was comparable to that of the control cells. These results suggest that the Hbo1-Brd1 HAT complex and presumably acetylation at H3K14 are required in the initiation of *Cd8* transcription at the transition of DN to DP stage, but once the *Cd8* transcription is activated by the compensatory action of other HATs, it can be maintained even in the absence of Brd1. Nevertheless, failure of CD8 $\alpha\alpha$  induction in CD4 T cells in the gut indicates that Brd1 is required to reactivate *Cd8* transcription even in the peripheral T cells. These findings highlight the role of the Hbo1-Brd1 HAT complex in the activation but not the maintenance of *Cd8* expression.

Of note, *Brd1*<sup>-/-</sup> CD4 T cells also showed significantly lower chimerism in PB, although the capacity of *Brd1*<sup>-/-</sup> peripheral CD4 T cells to repopulate in immunocompromised host mice was almost intact. We therefore suspected that the reduced chimerism of *Brd1*<sup>-/-</sup> CD4 T cells in the periphery could be attributed to the impaired egress from the thymus to the periphery. Indeed, the expression of SIP<sub>1</sub>, which is critical for CD4 SP thymocytes to egress from the thymus, showed a mild, albeit not statistically significant, reduction in *Brd1*<sup>-/-</sup> CD4<sup>+</sup>TCRβ<sup>high</sup> thymocytes, suggesting a moderate defect of *Brd1*<sup>-/-</sup> CD4 SP thymocytes in egression into the periphery. In addition, given the substantial difference in gene expression profiles between WT and *Brd1*<sup>-/-</sup> peripheral CD4 T cells (Fig. 3b), *Brd1* could also be necessary to endow appropriate integrity to CD4 SP thymocytes during terminal differentiation process. Furthermore, *Brd1*<sup>-/-</sup> peripheral CD4 T cells were demonstrated to be defective in producing cytokines. Together, all these findings implicate *Brd1* in various aspects of the immune cell development and functions.

Advances in epigenetic research are revealing the fine epigenetic regulations that control developmentally regulated gene expression, including those involved in haematolymphopoiesis<sup>20,21</sup>. Our findings in this study provide novel insights into epigenetic control of T-cell development. Characterization of the crosstalk between the Hbo1-Brd1 HAT complex and other regulators would promote the understanding of the complex regulation of the co-receptor expression, an essential step in the development of thymocytes.

## Methods

### Mice and gene targeting of *Brd1*

For conditional deletion of *Brd1*, the targeting vector was designed as in Fig. 1, and *Brd1*<sup>fl/fl</sup> mice were generated using R1 embryonic stem (ES) cells according to the conventional protocol. *Brd1*<sup>fl/fl</sup> mice were backcrossed to the C57BL/6 background more than seven times and crossed with Tie2-Cre mice<sup>9</sup>. Eight-week-old female C57BL/6 (CD45.2) mice were purchased from Japan SLC. Eight-week-old female C57BL/6 mice congenic for the Ly5 locus (CD45.1) were purchased from Sankyo-Lab Service Corporation. OT-I mice (C57BL/6) were purchased from the Jackson Laboratory. Mice were bred and maintained in the Animal Research Facility of the Graduate School of Medicine, Chiba University in accordance with institutional guidelines.

### Flow cytometry and antibodies

The mAbs were purchased from BD Biosciences, eBioscience or BioLegend. For analysis of co-receptor expression in adult thymocytes, cells were stained with CD45.2-PacificBlue (1:200, 104), CD4-APC (1:50, GK1.5), CD8α-PE (1:25, 53–6.7) and TCRβ chain-APC/Cy7 (1:50, H57–597). For fetal DN thymocytes, cells were stained with CD3ε-Brilliant Violet (1:50, 145–2C11), CD4-Biotin (1:50, GK1.5), CD8-APC/Cy7 (1:50, 53–6.7), CD25-APC (1:50, PC61), CD44-PE (1:50, IM7) and CD69-PE/Cy7 (1:50, H1.2F3). A biotin-labelled CD4 antibody was visualized with Streptavidin (1:50, PE/Cy7). For cell cycle analysis, incorporated BrdU was measured by using APC BrdU Flow Kit (BD Biosciences) according to the manufacturer's protocol on gated DP, CD4 SP, CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> and CD8 SP cells. For PB cells, CD45.1-PE/Cy7 (1:50, A20), CD45.2-FITC (1:50, 104), B220-APC



(1:50, RA3–6B2), Gr-1-PE (1:200, RB6–8C5), Mac-1-PE (1:200, M1/70), CD4-APC/Cy7 or -APC (1:50, RM4–5 or 1:50, GK1.5) and CD8 $\alpha$ -APC/Cy7 or -PE (1:50, 53-6.7) were used. Other antibodies used are  $\gamma\delta$ TCR-biotin (1:50, GL3), NK1.1 (PK136), CD11c (N418), CD25-APC (1:50, PC61) and CD44-PE (1:50, IM7). Dead cells were eliminated by staining with propidium iodide (1  $\mu$ g ml<sup>-1</sup>; Sigma-Aldrich). For Annexin V staining, cells were suspended with 1xAnnexin binding buffer and stained with FITC-Annexin V following the manufacturer's protocol (BD Biosciences). All flow cytometric analyses and cell sorting were performed on FACS Aria II or FACS-Canto II (BD Biosciences). IELs were isolated as previously described<sup>22</sup>.

### DN3 culture

Using a biotinylated lineage mixture [Gr-1, Mac-1, Ter-119, B220 (1:40), CD4, CD8 $\alpha$  (1:10),  $\gamma$  TCR, CD3 $\epsilon$ , CD11c and NK1.1 (1:20)], CD25-APC(1:50, PC61) and CD44-PE(1:50, IM7), Lin<sup>-</sup>CD25<sup>+</sup>CD44<sup>+</sup> DN3 thymocytes were sorted on a FACS Aria II. DN3 cells were cultured on TSt-4/DLL stromal cells with 10 ng ml<sup>-1</sup> SCF, IL-7 and Flt3L (PeproTech) supplemented only for the initial 24 h. For rescue experiments, *Brd1*<sup>-/-</sup> DN1/2 or DN3 cells were transduced with a *Brd1* retrovirus (pMC-3xFlag-Brd1-IRES-EGFP<sup>8</sup>) on TSt-4/DLL stromal cells. Transduced GFP<sup>+</sup> cells were purified by cell sorting and then cultured as described above.

### Competitive repopulating assay of peripheral CD4 T cells

We transferred 1  $\times$  10<sup>6</sup> CD45.2 CD4 T cells purified from the *Tie2-Cre* control and *Tie2-Cre;Brd1<sup>fl/fl</sup>* spleen into sublethally irradiated NOG mice (2.0 Gy) along with the same number of CD45.1 splenic CD4 T cells (competitor cells). Chimerism of CD45.1 competitor CD4 T cells and CD45.2 test CD4 T cells in the PB was monitored weekly.

### Induction of Th1 and Th2 cytokine expression

CD4<sup>+</sup> T cells with a naive phenotype (CD4<sup>+</sup>CD62L<sup>hi</sup>) were purified with a FACS Aria cell sorter (Becton Dickinson), which yielded a purity of >98%, and were used as naive CD4<sup>+</sup> T cells. Naive CD4<sup>+</sup> T cells (1.5  $\times$  10<sup>6</sup>) were stimulated for 2 days with immobilized mAb to TCR $\beta$  (10  $\mu$ g ml<sup>-1</sup>; H57-597) plus soluble mAb to CD28 (1  $\mu$ g ml<sup>-1</sup>; 37.51; BioLegend) in the presence of IL-2 (15 ng ml<sup>-1</sup>), IL-12 (10 ng ml<sup>-1</sup>; Wako) and mAb to IL-4 (5  $\mu$ g ml<sup>-1</sup>; 11B11) for Th1 conditions, or in the presence of IL-2 (15 ng ml<sup>-1</sup>), IL-4 (100 ng ml<sup>-1</sup>; PeproTech) and mAb to IFN- $\gamma$  (5  $\mu$ g ml<sup>-1</sup>; R4-6A2) for Th2 conditions. Cells were cultured for an additional 4 days without stimulation of the TCR in the presence of the original cytokines. Cultured cells were restimulated for 6 h with immobilized mAb to TCR $\beta$  (10  $\mu$ g ml<sup>-1</sup>), and intracellular staining was done as described<sup>23</sup>.

### BM transplantation

BM cells from B6-CD45.2 mutant mice (test cells) were transplanted intravenously into 8-week-old B6-CD45.1 recipients irradiated at a dose of 9.5 Gy with or without BM cells from 8-week-old B6-CD45.1 congenic mice (competitor cells).

## Immunoprecipitation and GST pull-down assay

293T cells were transfected with pcDNA3-Flag-human Runx1, human Runx3 or mouse Ikaros together with either pcDNA3-HA-mouse Brd1 or mouse Hbo1. The cells were lysed in lysis buffer containing 250 mM NaCl and then immunoprecipitation was performed using anti-FLAG M2 affinity gel. Immunocomplexes were eluted with FLAG peptide. Histone proteins were extracted following the method described previously<sup>24</sup>. For GST pull-down assays, DNA fragments encoding the full-length human Runx1 and Runx3 were subcloned into the pGEX6p vector. GST fusion proteins were expressed in BL21 (DE3) cells. For the GST pull-down assay, HA-tagged Brd1 or Hbo1 was translated *in vitro* using a TNT reticulocyte lysate transcription/translation system (Promega) and mixed with GST-fusion proteins. The reaction was carried out in lysis buffer containing 150 mM NaCl at 4 °C for 2 h and the beads were washed four times with the same buffer. Proteins were separated by sodium dodecyl sulfate–PAGE (SDS–PAGE), transferred to a PVDF membrane and detected by western blotting using the following antibodies at a 1:1,000 dilution except for anti-histone H3 (1:2,000): anti-FLAG (clone M2; Sigma), anti-HA (clone 3F10; Roche), anti-HA (rabbit IgG, Santa Cruz), anti-acetyl-histone H3 (lys9), anti-acetyl-histone H3 (lys14), anti-histone H3 (rabbit IgG; Millipore), anti-acetyl-histone H4 (lys5) (clone EP1000Y), anti-acetyl-histone H4 (lys8), anti-acetyl-histone H4 (lys12), anti-acetyl-histone H4 (lys16) and anti-histone H4 (rabbit IgG; Millipore). Uncropped raw scans of blots used in the figures are presented in Supplementary Figs 6–8.

## Microarray analysis

Gene expression profiles were evaluated using the Agilent one-colour microarray-based gene expression platform according to the manufacturer's instructions (Low Input Quick Amp Labeling). Total RNA (10 ng) was amplified and labelled using the one-colour Quick Amp labeling kit (51900612; Agilent Technologies). Complementary RNA (cRNA) samples were hybridized onto SurePrint G3 Mouse GE 8 × 60 K Microarray (G4852A, Agilent Technologies). The microarray numerical values were analysed using the GeneSpring GX 11.5.1 software (Agilent Technologies). For clustering analysis, the Ward's linkage rule was applied to all expressed genes in each sorted cells. Microarray and ChIP-sequence data were deposited in Gene Expression Omnibus (accession number GSE48797).

## qRT-PCR

Total RNA was isolated using TRIZOL LS solution (Invitrogen) and reverse-transcribed by the ThermoScript RT-PCR system (Invitrogen) with an oligo-dT primer or random hexamers. Real-time quantitative RT-PCR (qRT-PCR) was performed with an ABI Prism 7300 Thermal Cycler (Applied Biosystems) using SYBR Premix Ex TaqII (TaKaRa) and primers listed in Supplementary Table 2.

## Chromatin immunoprecipitation assay

AKR1 DP T cells expressing 3 × Flag-Brd1 (AKR1/Brd1 cells) or HA-Hbo1 (AKR1/Hbo1 cells) were prepared. Primary thymocytes and AKR1 cells were crosslinked with 1% formaldehyde for 5–10 min at 37 °C, washed two times with W&B buffer (100 mM Na Phosphate (pH7.0) and 0.1% Tween 20), and lysed with RIPA buffer (10 mM Tris (pH 8.0),

140 mM NaCl, 1 mM EDTA, 1% TritonX-100, 0.1% SDS, 0.1% Sodium deoxycholate (DOC) and protease inhibitor cocktail) and sonicated 15 times for 20 s using a Bioruptor (Cosmo Bio). The average chromatin fragment size after sonication was ~200–300 bp. After centrifugation, the soluble chromatin fraction was recovered, precleared for 1 h at 4 °C with a mixture of Protein A and G-conjugated Dynabeads (Invitrogen) blocked with BSA and salmon sperm DNA (Invitrogen), and then incubated with an anti-Flag, an anti-HA or an anti-acetyl H3K14 antibody (07–449; Millipore) for 2 h at 4 °C. Chromatin was immunoprecipitated overnight at 4 °C with antibody-conjugated Dynabeads. The immunoprecipitates were extensively washed with the following combination of wash buffers; RIPA buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% TritonX-100, 0.1% SDS, 0.1% DOC and protease inhibitor cocktail), high salt (500 mM NaCl) RIPA buffer, LiCl wash buffer (10 mM Tris-HCl (pH 8.0), 250 mM LiCl, 1 mM EDTA, 0.5% NP40 and 0.5% DOC) and TE buffer (10 mM Tris-HCl (pH 8.0) and 1 mM EDTA). Bound chromatin and input DNA were placed in elution buffer (10 mM Tris-HCl (pH 8.0), 5 mM EDTA, 300 mM NaCl and 0.5% SDS) and reverse crosslinked. Immunoprecipitated DNA and input DNA were treated with RNase A (Sigma-Aldrich) and proteinase K (Roche). To separate DNA from protein fragments, phenol-chloroform is used in conjunction with a standard DNA purification method. For ChIP assay, quantitative PCR was performed with an ABI prism Step One Plus real time PCR system using SYBR Premix Ex Taq II (Takara Bio). The primer sequences are listed in Supplementary Table 2.

### Statistical analysis

Statistical tests were carried out using Graph Pad Prism version 6.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


### Acknowledgments

We thank Dr Motomi Osato for providing the human RUNX1 and RUNX3 cDNAs and George R Wendt and Ola Mohammed Kamel Rizq for critical reading of the manuscript. This work was supported in part by Grants-in-aid for Scientific Research (#24249054) and Scientific Research on Innovative Areas ‘Stem Cell Aging and Disease’ (#25115002), ‘Cancer Stem Cell’ (#25130702) and ‘Genome Science’ (#221S0002) from MEXT, Japan, a Grant-in-aid for Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Corporation (JST), and grants from the Takeda Science Foundation and the Uehara Memorial Foundation.


### References

1. Taniuchi I, Ellmeier W. Transcriptional and epigenetic regulation of CD4/CD8 lineage choice. *Adv Immunol.* 2011; 110:71–110. [PubMed: 21762816]
2. Ellmeier W, Sunshine MJ, Maschek R, Littman DR. Combined deletion of CD8 locus cis-regulatory elements affects initiation but not maintenance of CD8 expression. *Immunity.* 2002; 16:623–634. [PubMed: 12049715]
3. Garefalaki A, et al. Variegated expression of CD8 alpha resulting from in situ deletion of regulatory sequences. *Immunity.* 2002; 16:635–647. [PubMed: 12049716]
4. Feik N, et al. Functional and molecular analysis of the double-positive stage-specific CD8 enhancer E8III during thymocyte development. *J Immunol.* 2005; 174:1513–1524. [PubMed: 15661911]

5. Harker N, et al. The CD8alpha gene locus is regulated by the Ikaros family of proteins. *Mol Cell*. 2002; 10:1403–1415. [PubMed: 12504015]
6. Chi TH, et al. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. *Nature*. 2002; 418:195–199. [PubMed: 12110891]
7. Lee PP, et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. *Immunity*. 2001; 15:763–774. [PubMed: 11728338]
8. Mishima Y, et al. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. *Blood*. 2011; 118:2443–2453. [PubMed: 21753189]
9. Kisanuki YY, et al. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis *in vivo*. *Dev Biol*. 2001; 230:230–242. [PubMed: 11161575]
10. Matloubian M, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. *Nature*. 2004; 427:355–360. [PubMed: 14737169]
11. Yuan J, Crittenden RB, Bender T. P c-Myb promotes the survival of CD4 + CD8 + double-positive thymocytes through upregulation of Bcl-xL. *J Immunol*. 2010; 184:2793–2804. [PubMed: 20142358]
12. Rothenberg EV, Moore JE, Yui MA. Launching the T-cell-lineage developmental programme. *Nat Rev Immunol*. 2008; 8:9–21. [PubMed: 18097446]
13. Hogquist KA, et al. T cell receptor antagonist peptides induce positive selection. *Cell*. 1994; 76:17–27. [PubMed: 8287475]
14. Hayday A, Theodoridis E, Ramsburg E, Shires J. Intraepithelial lymphocytes: exploring the Third Way in immunology. *Nat Immunol*. 2001; 2:997–1003. [PubMed: 11685222]
15. Mucida D, et al. Transcriptional reprogramming of mature CD4 + helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. *Nat Immunol*. 2013; 14:281–289. [PubMed: 23334788]
16. Collins A, Littman DR, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. *Nat Rev Immunol*. 2009; 9:106–115. [PubMed: 19165227]
17. Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. *Biochim Biophys Acta*. 2014; 1839:627–643. [PubMed: 24631868]
18. Agalioti T, Chen G, Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. *Cell*. 2002; 111:381–392. [PubMed: 12419248]
19. Vicent GP, et al. Two chromatin remodeling activities cooperate during activation of hormone responsive promoters. *PLoS Genet*. 2009; 5:e1000567. [PubMed: 19609353]
20. Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. *Nat Rev Immunol*. 2011; 11:478–488. [PubMed: 21660052]
21. Oshima M, Iwama A. Epigenetics of hematopoietic stem cell aging and disease. *Int J Hematol*. 2014; 100:326–334. [PubMed: 25082353]
22. Mucida D, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science*. 2007; 317:256–260. [PubMed: 17569825]
23. Yamashita M, et al. Crucial role of MLL for the maintenance of memory T helper type 2 cell responses. *Immunity*. 2006; 24:611–622. [PubMed: 16713978]
24. Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N, Nozaki N. The organization of histone H3 modifications as revealed by a panel of specific monoclonal antibodies. *Cell Struct Funct*. 2008; 33:61–73. [PubMed: 18227620]



**Figure 1. Deregulated T-cell development in the *Brd1*-deficient thymus**  
**(a)** Strategy for making a conditional knockout allele for *Brd1* by homologous recombination in ES cells. FRT recombinase was used to remove the *TK-Neo* cassette. **(b)** Absolute numbers of total thymocytes from *Tie2-Cre (Brd1<sup>+/+</sup>)* and *Tie2-Cre;Brd1<sup>fl/fl</sup> (Brd1<sup>-/-</sup>)* mice. Data are presented as mean±s.d. (*Brd1<sup>+/+</sup>*, *n*=5; *Brd1<sup>-/-</sup>*, *n*=4). **(c)** Representative flow cytometric profiles of CD4 and CD8 expression in thymic T cells from 8- to 11-week-old *Tie2-Cre (Brd1<sup>+/+</sup>)* and *Tie2-Cre;Brd1<sup>fl/fl</sup> (Brd1<sup>-/-</sup>)* mice. Proportion of each gate is indicated. **(d)** Representative flow cytometric profiles of TCRβ expression in DP, CD4 SP and CD8 SP cells gated in **(c)**. Percentages of TCRβ<sup>hi</sup> and TCRβ<sup>low</sup> cells are shown (*Brd1<sup>+/+</sup>* in blue and *Brd1<sup>-/-</sup>* in red). **(e)** Frequencies of indicated cell populations in total thymocytes from 8- to 11-week-old *Tie2-Cre (Brd1<sup>+/+</sup>)* and *Tie2-Cre;Brd1<sup>fl/fl</sup> (Brd1<sup>-/-</sup>)* mice. Data are presented as mean±s.d. (*Brd1<sup>+/+</sup>*, *n*=5; *Brd1<sup>-/-</sup>*, *n*=4). **(f)** Representative flow cytometric profiles of CD8 expression in thymic T cells in **(c)**. **(g)** Frequencies of myeloid (Gr-1<sup>+</sup> and/or Mac-1<sup>+</sup>), B (B220<sup>+</sup>) or T (CD4<sup>+</sup> and CD8<sup>+</sup>) cells in CD45<sup>+</sup> PB mononuclear cells from 8- to 11-week-old *Tie2-Cre (Brd1<sup>+/+</sup>)* and *Tie2-Cre;Brd1<sup>fl/fl</sup> (Brd1<sup>-/-</sup>)* mice. Data are presented as mean±s.d. (*Brd1<sup>+/+</sup>*, *n*=10; *Brd1<sup>-/-</sup>*, *n*=8). \**P*<0.05, \*\**P*<0.01 and \*\*\**P*<0.001 (Student's *t*-test).




### Figure 2. Cell autonomous defect of T cells in the absence of Brd1

(a) Surface expression of CD4 and CD8 on *Brd1*<sup>Δ/Δ</sup> cells in recipient mice. BM cells from *Tie2-Cre* control (*Brd1*<sup>+/+</sup>) and *Tie2-Cre;Brd1<sup>fl/fl</sup>* (*Brd1*<sup>Δ/Δ</sup>) mice (CD45.2<sup>+</sup>) were transplanted into lethally irradiated wild-type recipient mice (CD45.1<sup>+</sup>) along with the same number of BM competitor cells (CD45.1<sup>+</sup>). Representative flow cytometric profiles of CD4 and CD8 expression in CD45.2<sup>+</sup> donor-derived T cells in the thymus at 6 months post-transplantation are depicted. The proportion of each gate is indicated. (b) Frequencies of indicated cell populations in CD45.2<sup>+</sup> donor-derived T cells in (a). Data are presented as mean±s.d. (*Brd1*<sup>+/+</sup>, *n* =5; *Brd1*<sup>Δ/Δ</sup>, *n* =5). (c) Contribution of *Brd1*<sup>Δ/Δ</sup> haematopoietic cells to the PB T lymphocytes of recipient mice in (a). Chimerism of donor-derived CD45.2<sup>+</sup> *Brd1*<sup>Δ/Δ</sup> cells in the PB at 12 weeks post-transplantation is shown as mean±s.d. (*Brd1*<sup>+/+</sup>, *n* =6; *Brd1*<sup>Δ/Δ</sup>, *n* =6). (d) Contribution of *Brd1*<sup>Δ/Δ</sup> haematopoietic cells to the PB in recipient mice. BM cells from *Tie2-Cre* control (*Brd1*<sup>+/+</sup>) and *Tie2-Cre;Brd1<sup>fl/fl</sup>* mice (*Brd1*<sup>Δ/Δ</sup>) (CD45.2<sup>+</sup>) were transplanted into lethally irradiated wild-type recipient mice (CD45.1<sup>+</sup>) without any BM competitor cells. Chimerism of donor-derived CD45.2<sup>+</sup> *Brd1*<sup>Δ/Δ</sup> cells in the PB at 12 weeks post-transplantation is shown as mean±s.d. (*Brd1*<sup>+/+</sup>, *n* =6; *Brd1*<sup>Δ/Δ</sup>, *n*



=6). (e) Competitive repopulating capacity of *Brd1*<sup>-/-</sup> peripheral CD4 T cells. CD4 T cells from the *Tie2-Cre* control and *Tie2-Cre;Brd1<sup>fl/fl</sup>* spleen ( $1 \times 10^6$  each, CD45.2) were transferred into sublethally irradiated NOG mice along with the same number of CD45.1 splenic CD4 T cells (competitor cells). Chimerism of CD45.2<sup>+</sup> *Brd1*<sup>-/-</sup> CD4 T cells in the PB CD4<sup>+</sup>TCR $\beta$ <sup>+</sup> T-cell pool is plotted as dots and mean values are indicated as bars. (f) Expression of S1P receptors in *Brd1*<sup>-/-</sup> CD4<sup>+</sup>TCR $\beta$ <sup>high</sup> thymocytes. Quantitative RT-PCR analysis of the expression of S1P receptor genes in *Brd1*<sup>+/+</sup> and *Brd1*<sup>-/-</sup> CD4<sup>+</sup>TCR $\beta$ <sup>high</sup> thymocytes was performed. *Hprt1* was used to normalize the amount of input RNA. ND =not detected. \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  (Student's *t*-test).



**Figure 3. Inefficient activation of *Cd8* genes in *Brd1*-deficient DP thymocytes**

(a) Cell cycle status of repopulated thymocytes. Percentages of cells in S phase in the indicated populations of thymocytes from the recipient mice in Fig. 2d were measured by detecting incorporated BrdU by flow cytometry at 2 h post-intraperitoneal injection of BrdU. Data are presented as mean±s.d. (*Brd1*<sup>+/+</sup>, *n*=4; *Brd1*<sup>Δ/Δ</sup>, *n*=3). (b) Hierarchical clustering of gene expression patterns of the indicated cell fractions obtained in microarray analyses. For clustering analysis, the Ward's linkage rule was applied to all expressed genes in each of the sorted cells. The Ward's linkage scores are indicated on the top. (c) A scatter diagram of microarray analysis. The average signal levels of indicated cell fractions compared with those of *Brd1*<sup>Δ/Δ</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> cells are plotted. The upper and lower lines represent the borderline for a twofold increase and a twofold decrease, respectively. (d)


Quantitative RT-PCR analysis of the expression of the genes indicated in *Brd1*<sup>+/+</sup> and *Brd1*<sup>-/-</sup> thymocytes. *Hprt1* was used to normalize the amount of input RNA. **(e)** Representative flow cytometric profiles of CD4 and CD8 expression in thymic T cells from 8- to 11-week-old *Tie2-Cre* (*Brd1*<sup>+/+</sup>) and *Tie2-Cre;Brd1*<sup>fl/fl</sup> (*Brd1*<sup>-/-</sup>) mice expressing OT-I TCR transgene. Proportion of each gate is indicated. Data are representative of three independent experiments. **(f)** Representative flow cytometric profiles of CD4 and CD8 expression in PB of *Brd1*<sup>+/+</sup> OT-I and *Brd1*<sup>-/-</sup> OT-I mice (left panels). Proportion of each gate is indicated. CD8 expression in PB T cells is also depicted in histograms (right panel).

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




**Figure 4. *In vitro* differentiation of *Brd1*<sup>-/-</sup> DN3 cells**

DN3 cells from *Tie2-Cre* control (*Brd1*<sup>+/+</sup>) and *Tie2-Cre;Brd1<sup>fl/fl</sup>* (*Brd1*<sup>-/-</sup>) mice were seeded on TSt-4/DLL stromal cells in triplicate and their differentiation was monitored. Cytokines (10 ng ml<sup>-1</sup> SCF, IL-7 and Flt3L) were supplemented only for the initial 24 h. Representative CD4 and CD8 expression profiles from the three repeated experiments are depicted. The proportion of each gate is indicated.



**Figure 5. Impaired CD8 expression in IEL subsets in the absence of Brd1**

Expression of CD8α in TCRβ<sup>+</sup>, CD4<sup>+</sup>TCRβ<sup>+</sup> and γδTCR<sup>+</sup> IELs was analysed in *Tie2-Cre* control (*Brd1*<sup>+/+</sup>) and *Tie2-Cre;Brd1<sup>fl/fl</sup>* (*Brd1*<sup>-/-</sup>) mice. Representative flow cytometric profiles from the two repeated experiments with a proportion of each gate (left panels) and the percentages of CD8α<sup>+</sup> cells in the indicated cell populations with mean values (right panels) are shown. \*\**P*<0.01 and \*\*\**P*<0.001 (Student's *t*-test).




**Figure 6. Brd1-Hbo1 complex acetylates H3K14 at the *Cd8* gene loci**

(a) Levels of acetylation at histone H3 and H4 in total thymocytes from *Tie2-Cre* (*Brd1*<sup>+/+</sup>) and *Tie2-Cre;Brd1<sup>fl/fl</sup>* (*Brd1*<sup>-/-</sup>) thymus. Histones purified from thymocytes were analysed by western blotting using the indicated antibodies. (b) Levels of H3K14 acetylation at the enhancers and promoters of the *Cd8a* and *Cd8b1* genes. Schematic representation of the *Cd8a* and *Cd8b1* gene loci and the location of the primer sets are depicted (upper panel). The binding of Brd1 and Hbo1 to the *Cd8a* and *Cd8b1* gene loci was determined by ChIP using an anti-Flag antibody in AKR1/3 × Flag-Brd1 cells and anti-HA antibody in AKR1/HA-Hbo1 cells, respectively. The relative amount of immunoprecipitated DNA is depicted as a percentage of input DNA. An isotype control IgG was used as a negative



control. The *Cd4* silencer element and *p16* promoter served as controls. The data are shown as the mean±s.d. for triplicate PCRs (middle panel). ChIP analyses were performed using *Brd1*<sup>+/+</sup> and *Brd1*<sup>-/-</sup> DP cells and *Brd1*<sup>-/-</sup> CD4<sup>+</sup>CD8<sup>-</sup>TCRβ<sup>-low</sup> cells purified by cell sorting and an anti-acetylated H3K14 antibody. The relative amount of immunoprecipitated DNA is depicted as a percentage of input DNA. The *Cd4* silencer element served as a control. The data are shown as the mean±s.d. for triplicate PCRs (lower panel). (c) Brd1 and Hbo1 directly interact with Runx proteins. 293T cells were transfected with Flag-tagged Runx1 or Runx3 together with either HA-tagged Brd1 or Hbo1. Runx proteins were immunoprecipitated using an anti-Flag antibody, and then immunoprecipitates were detected by immunoblotting using anti-Flag and anti-HA antibodies (upper and middle panels). The direct interactions between Runx proteins with Brd1 and Hbo1 were confirmed by GST-pull down assays using GST-Runx1 and GST-Runx3 fusion proteins and *in vitro* translated HA-tagged Brd1 and Hbo1 following immunoblotting using an anti-HA antibody (lower panels). (d) Brd1 and Hbo1 directly interact with Ikaros proteins. 293T cells were transfected with Flag-tagged Ikaros together with either HA-tagged Brd1 or Hbo1. Ikaros protein was immunoprecipitated using an anti-Flag antibody, and then immunoprecipitates were detected by immunoblotting using anti-Flag and anti-HA antibodies.



**Figure 7. *In vitro* differentiation of *Brd1*<sup>-/-</sup> DN3 cells**

**(a)** DN3 thymocytes from *Tie2-Cre;Brd1<sup>fl/fl</sup>* (*Brd1*<sup>-/-</sup>) mice were seeded on TSt-4/DLL stromal cells in the presence of 10 ng/ml<sup>-1</sup> SCF, IL-7 and Flt3L and transduced with a *Brd1* retrovirus. At day 3 post-transduction, transduced GFP<sup>+</sup> cells were purified by cell sorting and further cultured on TSt-4/DLL stromal cells in the presence of 2 ng ml<sup>-1</sup> SCF, IL-7 and Flt3L for 7 to 10 days. DN3 thymocytes from *Tie2-Cre* (*Brd1*<sup>+/+</sup>) and *Tie2-Cre;Brd1<sup>fl/fl</sup>* (*Brd1*<sup>-/-</sup>) mice without transduction served as controls. Representative CD4 and CD8 expression profiles from three repeated experiments are depicted. The proportion of each gate is indicated. **(b)** Levels of acetylation at H3K14 in rescued DP cells. DP cells were derived from *Brd1*-transduced *Brd1*<sup>-/-</sup> DN1/2 thymocytes (*Brd1*<sup>-/-</sup> DP/Brd1, lane 4) and from WT DN1/2 thymocytes (*Brd1*<sup>+/+</sup> DP/mock, lane 3) as in **(a)** and were subjected to western blotting using an anti-H3K14ac antibody (left panel). DP thymocytes from *Tie2-Cre* (*Brd1*<sup>+/+</sup> DP, lane 1) and *Tie2-Cre;Brd1<sup>fl/fl</sup>* (*Brd1*<sup>-/-</sup> DP, lane 2) thymus served as controls.